ArticleChina CDC weekly2022
The Incidence, Mortality, and DALYs Trends Associated with Esophageal Cancer - China, 1990-2019.
Article in China CDC weekly, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Long-term trends in disease burden of esophageal cancer in China and the forecast until 2050.BMC gastroenterology · 2026Article
- Snail family transcriptional repressor 1 radiosensitizes esophageal cancer via epithelial-mesenchymal transition signaling: From bioinformatics to integrated study.World journal of gastrointestinal oncology · 2025Article
- Catching cancer signals in the blood: Innovative pathways for early esophageal cancer diagnosis.World journal of gastroenterology · 2025Article
- Plasma DNA methylation detection for early screening, diagnosis, and monitoring of esophageal adenocarcinoma and squamous cell carcinoma.World journal of gastroenterology · 2024Article
- Mortality burden and future projections of major risk factors for esophageal cancer in China from 1990 to 2019.General thoracic and cardiovascular surgery · 2024Article
- Disease burden and related risk factors of esophageal cancer in China and globally from 1990 to 2021, with forecast to 2035: An analysis and comparison.Tobacco induced diseases · 2024Article
- Application of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy in Individualized Treatment of Esophageal Cancer.Biomedicines · 2023Review
- Analysis of living habit risk factors for esophageal cancer in central China: A bi-center case-control study.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Esophageal cancer (EC) is one of the most common malignant tumors in China. The new cases and deaths in China account for more than half of the world, and the disease burden of esophageal cancer is serious. What is added by this report?: From 1990 to 2019, the disease burden of EC in China showed a decrease overall; it first increased between 1990 and 2004, but then decreased between 2004 and 2019. The burden of EC in men was much higher than that in women. Age was an important factor affecting the burden of EC, with disease burden rising rapidly after 40 years old. What are the implications for public health practices?: The screening, early diagnosis, and treatment for EC should continue to be strengthened in China. Middle-aged and elderly men are high-risk groups of EC and should be a key population for EC prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.